Different Perspectives on the Burden of Disease
What do medical market research and health economic outcomes research have in common? How can we combine our work on burden of disease in a way that realizes it fullest potential? What can we learn from each other’s approach?
View Oct 27, 2021
Precision vs Imprecision Oncology
I got to thinking recently about the push towards developing drugs for molecularly stratified patient populations, including a spate of approvals over the past few years for agents targeting aberrantly expressed (mutated, translocated, amplified, etc.) proteins, as opposed to many of the blockbuster drugs (based on WW sales — see data, right, from EvaluatePharma) that are not “precision medicine” agents.
View Jul 29, 2021